Research achievement

Prof Rawat has significantly contributed in the area of drug development and one of the molecule that his group developed at University of Delhi has entered in Phase I human clinical trials for the treatment of Parkinson disease and it resulted a publication in Nature Communications (ACS Med Chem Lett 2019, 2012; IN 283657, 2017); [ES2899730T3 (2022); CA3175047A1 (2022); EP3971178A1 (2022); US20170209441A1 (2021); PT2822936T (Portugal, 2021); US9567316B2 (2017); IN 283657 (2017); WO 2013 134047A3 (20213).]. Phase I human clinical trials began in October 2023.

Media Relation

March 29, 2023

NurrOn entered into co-development agreement with HanAll Biopharma and Daewoong Pharmaceuticals to develop ATH-399A for Parkinson's disease.

https://www.prnewswire.com/news-releases/hanall-biopharma-and-daewoong-pharmaceutical-enter-into-co-development-agreement-with-nurron-pharmaceuticals-to-develop-therapy-for-parkinsons-disease-301834508.html

December 1, 2022

NurrOn received the award of the translational pipeline program 2022 for a Phase I trial of ATH-399A from Michael J. Fox Foundation.

https://www.michaeljfox.org/grant/development-nurr1-activator-novel-therapeutic-parkinsons-disease



(12) United States Patent Rawat et al.

(54) AMINOQUINOLINE DERIVATIVES AND USES THEREOF

(71) Applicants: UNIVERSITY OF DELHI, Delhi (IN);
THE MCLEAN HOSPITAL
CORPORATION, Belmont, MA (US)

(72) Inventors: Diwan S. Rawat, Delhi (IN); Sunny Manohar, Delhi (IN); Ummadisetty Chinna Rajesh, Delhi (IN); Deepak Kumar, Delhi (IN); Anuj Thakur, Delhi (IN); Mohit Tripathi, Delhi (IN); Panyala Linga Reddy, Delhi (IN); Shamseer Kulangara Kandi, Delhi (IN); Satyapavan Vardhineni, Delhi (IN); Kwang-Soo Kim, Lexington, MA (US); Chun-Hyung Kim, Lexington, MA (US)

(73) Assignees: The McLean Hospital Corporation, Belmont, MA (US); University of Delhi, Delhi (IN)

(56) References Cited

(10) Patent No.:

(45) Date of Patent:

U.S. PATENT DOCUMENTS

US 11.026,943 B2

*Jun. 8, 2021

3,196,155	A	7/1965	Gailliot et al.
2003/0119026	AI	6/2003	Le et al.
2003/0229119	A1	12/2003	Kym et al.
2004/0072818	A1	4/2004	Dunning et al.
2005/0186591	A1	8/2005	Bumcrot et al.
2009/0226401	A1	9/2009	Kim et al.
2011/0251210	A 1	10/2011	Peyton et al.

FOREIGN PATENT DOCUMENTS

WO	00/59510 A1	10/2000
WO	03/070244 A1	8/2003
WO	2004/002960 A1	1/2004
WO	WO 2004/002960	1/2004
WO	2008/036374 A2	3/2008
WO	2009/148659 A2	12/2009
WO	2010/059738 A1	5/2010
wo	2010/065932 A1	6/2010

OTHER PUBLICATIONS

We have been working on nano-catalysis with a goal to develop a catalytic system that can be useful in making some of the Active Pharmaceutical Ingredients or industrially important chemicals. During this, we developed a catalytic system which can be used for the C-C bond formation and reduction of nitro compounds. This has resulted many high impact publications (12 papers in ACS Sus Chem Eng, IF = 9.088, Green Chem, Org. Lett., J. Org. Chem.).

One of the catalytic systems developed was used for the selective reduction of nitro compounds using hydrazine hydrate as a source of hydrogen and the process is being used for the synthesis of some industrially relevant molecules.

Research work Highlighted in the Cover Page:

- **Tetrahedron Letters** 59 (24), 13 June **2020**
- **Tetrahedron Letters** 59 (24), 13 June **2018**
- Tetrahedron Letters 57 (4), 5 October 2016
- ACS Sustainable Chemistry and Engineering 3 (1), 2015

Research work Highlighted by Synfacts:

Green Chemistry 22, 3170 (2020)
Tetrahedron Letters 59, 2341 (2018)
Chemistry - An Asian Journal 12, 785 (2017)
Tetrahedron Letters 57, 4468 (2016)
RSC Advances 6, 2935 (2016)
RSC Advances 5, 92121 (2015)

SYNFACTS 2020, 16(08): 0995 SYNFACTS 2018, 14(08): 0883 SYNFACTS 2017, 13(07), 0766 SYNFACTS 2016, 12(12), 1314 SYNFACTS 2016, 12(4), 0427 SYNFACTS 2016, 12(2), 0214

World.

प्रोफेसर दीवान एस रावत
एकएनएएससी, एफआरएससी, सीकेम (लंदन)
Professor Diwan S Rawat
FNASc, FRSC, CChem (London)
रसायन विज्ञान विभाग
Department of Chemistry
दिस्सी विश्वविद्यालय, दिस्सी-११०००७
University of Delhi, Delhi-1100007